Oscar Health, Inc. (OSCR) saw its shares tumble 8.30% in premarket trading on November 7, 2024, despite reporting solid revenue growth in the third quarter of 2024. The healthcare technology company's stock reacted negatively to a wider-than-expected loss for the quarter.
For the three months ended September 30, 2024, Oscar Health reported revenue of $2.42 billion, surpassing analysts' consensus estimate of $2.34 billion. This represented a 68.3% increase compared to the same period last year. The strong revenue growth was driven primarily by higher membership and rate increases, according to the company.
However, Oscar Health's net loss attributable to common shareholders widened to $54.6 million, or $0.22 per diluted share, missing the consensus estimate of a $0.19 loss per share. The company cited higher medical costs, primarily driven by higher Special Enrollment Period membership resulting in higher risk adjustment transfers, as well as higher COVID-related costs, for the larger-than-expected loss.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.